Furthermore, differently from previous reports that in vivo resistant AML cells express high levels of BCL2A1 and BCL2L1 [30,34], we found that both genes are down regulated in chemoresistant AML patients in comparison to those from the chemosensitive class. This evidence concerns the gene BCL2A1 and acute myeloid leukemia.